698 related articles for article (PubMed ID: 25283984)
1. AAV.shRNA-mediated downregulation of ROCK2 attenuates degeneration of dopaminergic neurons in toxin-induced models of Parkinson's disease in vitro and in vivo.
Saal KA; Koch JC; Tatenhorst L; Szegő EM; Ribas VT; Michel U; Bähr M; Tönges L; Lingor P
Neurobiol Dis; 2015 Jan; 73():150-62. PubMed ID: 25283984
[TBL] [Abstract][Full Text] [Related]
2. ROCK2 is a major regulator of axonal degeneration, neuronal death and axonal regeneration in the CNS.
Koch JC; Tönges L; Barski E; Michel U; Bähr M; Lingor P
Cell Death Dis; 2014 May; 5(5):e1225. PubMed ID: 24832597
[TBL] [Abstract][Full Text] [Related]
3. Knockdown of interleukin-1 receptor 1 is not neuroprotective in the 6-hydroxydopamine striatal lesion rat model of Parkinson's disease.
Walsh S; Gavin A; Wyatt S; O'Connor C; Keeshan K; Nolan YM; O'Keeffe GW; Sullivan AM
Int J Neurosci; 2015 Jan; 125(1):70-7. PubMed ID: 24628580
[TBL] [Abstract][Full Text] [Related]
4. Enhanced neurotrophic distribution, cell signaling and neuroprotection following substantia nigral versus striatal delivery of AAV2-NRTN (CERE-120).
Herzog CD; Brown L; Kruegel BR; Wilson A; Tansey MG; Gage FH; Johnson EM; Bartus RT
Neurobiol Dis; 2013 Oct; 58():38-48. PubMed ID: 23631873
[TBL] [Abstract][Full Text] [Related]
5. Delayed delivery of AAV-GDNF prevents nigral neurodegeneration and promotes functional recovery in a rat model of Parkinson's disease.
Wang L; Muramatsu S; Lu Y; Ikeguchi K; Fujimoto K; Okada T; Mizukami H; Hanazono Y; Kume A; Urano F; Ichinose H; Nagatsu T; Nakano I; Ozawa K
Gene Ther; 2002 Mar; 9(6):381-9. PubMed ID: 11960314
[TBL] [Abstract][Full Text] [Related]
6. AAV-mediated expression of BAG1 and ROCK2-shRNA promote neuronal survival and axonal sprouting in a rat model of rubrospinal tract injury.
Challagundla M; Koch JC; Ribas VT; Michel U; Kügler S; Ostendorf T; Bradke F; Müller HW; Bähr M; Lingor P
J Neurochem; 2015 Jul; 134(2):261-75. PubMed ID: 25807858
[TBL] [Abstract][Full Text] [Related]
7. Sonic hedgehog delivered by an adeno-associated virus protects dopaminergic neurones against 6-OHDA toxicity in the rat.
Dass B; Iravani MM; Huang C; Barsoum J; Engber TM; Galdes A; Jenner P
J Neural Transm (Vienna); 2005 Jun; 112(6):763-78. PubMed ID: 15586304
[TBL] [Abstract][Full Text] [Related]
8. Progressive neurodegenerative and behavioural changes induced by AAV-mediated overexpression of α-synuclein in midbrain dopamine neurons.
Decressac M; Mattsson B; Lundblad M; Weikop P; Björklund A
Neurobiol Dis; 2012 Mar; 45(3):939-53. PubMed ID: 22182688
[TBL] [Abstract][Full Text] [Related]
9. Progressive nigrostriatal terminal dysfunction and degeneration in the engrailed1 heterozygous mouse model of Parkinson's disease.
Nordströma U; Beauvais G; Ghosh A; Pulikkaparambil Sasidharan BC; Lundblad M; Fuchs J; Joshi RL; Lipton JW; Roholt A; Medicetty S; Feinstein TN; Steiner JA; Escobar Galvis ML; Prochiantz A; Brundin P
Neurobiol Dis; 2015 Jan; 73():70-82. PubMed ID: 25281317
[TBL] [Abstract][Full Text] [Related]
10. Increased progenitor cell proliferation and astrogenesis in the partial progressive 6-hydroxydopamine model of Parkinson's disease.
Aponso PM; Faull RL; Connor B
Neuroscience; 2008 Feb; 151(4):1142-53. PubMed ID: 18201835
[TBL] [Abstract][Full Text] [Related]
11. Noradrenaline neuron degeneration contributes to motor impairments and development of L-DOPA-induced dyskinesia in a rat model of Parkinson's disease.
Shin E; Rogers JT; Devoto P; Björklund A; Carta M
Exp Neurol; 2014 Jul; 257():25-38. PubMed ID: 24747357
[TBL] [Abstract][Full Text] [Related]
12. Neuroprotection by neuropeptide Y in cell and animal models of Parkinson's disease.
Decressac M; Pain S; Chabeauti PY; Frangeul L; Thiriet N; Herzog H; Vergote J; Chalon S; Jaber M; Gaillard A
Neurobiol Aging; 2012 Sep; 33(9):2125-37. PubMed ID: 21816512
[TBL] [Abstract][Full Text] [Related]
13. Comparison of the behavioural and histological characteristics of the 6-OHDA and α-synuclein rat models of Parkinson's disease.
Decressac M; Mattsson B; Björklund A
Exp Neurol; 2012 May; 235(1):306-15. PubMed ID: 22394547
[TBL] [Abstract][Full Text] [Related]
14. A potential target for the treatment of Parkinson's disease: effect of lateral habenula lesions.
Han B; Jin HJ; Song MY; Wang T; Zhao H
Parkinsonism Relat Disord; 2014 Nov; 20(11):1191-5. PubMed ID: 25219971
[TBL] [Abstract][Full Text] [Related]
15. Delivery of a GDNF gene into the substantia nigra after a progressive 6-OHDA lesion maintains functional nigrostriatal connections.
Kozlowski DA; Connor B; Tillerson JL; Schallert T; Bohn MC
Exp Neurol; 2000 Nov; 166(1):1-15. PubMed ID: 11031079
[TBL] [Abstract][Full Text] [Related]
16. rAAV-mediated nigral human parkin over-expression partially ameliorates motor deficits via enhanced dopamine neurotransmission in a rat model of Parkinson's disease.
Manfredsson FP; Burger C; Sullivan LF; Muzyczka N; Lewin AS; Mandel RJ
Exp Neurol; 2007 Oct; 207(2):289-301. PubMed ID: 17678648
[TBL] [Abstract][Full Text] [Related]
17. AAV-mediated inhibition of ULK1 promotes axonal regeneration in the central nervous system in vitro and in vivo.
Ribas VT; Vahsen BF; Tatenhorst L; Estrada V; Dambeck V; Almeida RA; Bähr M; Michel U; Koch JC; Müller HW; Lingor P
Cell Death Dis; 2021 Feb; 12(2):213. PubMed ID: 33637688
[TBL] [Abstract][Full Text] [Related]
18. RING finger protein 11 (RNF11) modulates susceptibility to 6-OHDA-induced nigral degeneration and behavioral deficits through NF-κB signaling in dopaminergic cells.
Pranski EL; Dalal NV; Sanford CV; Herskowitz JH; Gearing M; Lazo C; Miller GW; Lah JJ; Levey AI; Betarbet RS
Neurobiol Dis; 2013 Jun; 54():264-79. PubMed ID: 23318928
[TBL] [Abstract][Full Text] [Related]
19. Generation of a alpha-synuclein-based rat model of Parkinson's disease.
Recchia A; Rota D; Debetto P; Peroni D; Guidolin D; Negro A; Skaper SD; Giusti P
Neurobiol Dis; 2008 Apr; 30(1):8-18. PubMed ID: 18313315
[TBL] [Abstract][Full Text] [Related]
20. 6-OHDA injections into A8-A9 dopaminergic neurons modelling early stages of Parkinson's disease increase the harmaline-induced tremor in rats.
Kolasiewicz W; Kuter K; Berghauzen K; Nowak P; Schulze G; Ossowska K
Brain Res; 2012 Oct; 1477():59-73. PubMed ID: 22902616
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
